Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ROSY-D: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment

NCT05303532 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05303532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05303532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ROSY-D: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
April 19, 2022
Completion date
December 31, 2026
Enrollment
214 (estimated)
Sites
123

Conditions

As the registry lists them; a condition with its own page is linked.

cancer